NCT03228667 2026-01-14QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsImmunityBio, Inc.Phase 2 Active not recruiting40 enrolled
NCT03983954 2025-11-28Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.NeoTX Therapeutics Ltd.Phase 1 Active not recruiting120 enrolled
NCT01938612 2021-03-12A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid TumoursAstraZenecaPhase 1 Completed269 enrolled
NCT02658214 2020-08-20Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsAstraZenecaPhase 1 Completed32 enrolled
NCT02262741 2017-10-23A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck CancerMedImmune LLCPhase 1 Completed71 enrolled